In the new age of targeted chemotherapies cancer no longer has to be a death sentence - as long as it is caught early, diagnosed properly, and monitored extensively. The early detection and rapid assessment of tumors is frequently an impossible task due to the current available cancer diagnostic technology. Better detection methods are needed in order to keep up with the shift in treatment philosophies. Developing simple screening methods that are effective, cheap, and readily available will help catch cancer at an early stage and more effectively manage the disease. I present an approach for the development of PCC agents that are capable of selectively detecting only the cancerous versions of proteins over the healthy, normal ones - also providing new avenues for targeted chemotherapies.